155.28
Glaukos Corporation Stock (GKOS) Latest News
How To Trade (GKOS) - Stock Traders Daily
Trust Point Inc. Has $972,000 Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Short Interest Up 18.3% in January - MarketBeat
Piper Sandler raises Glaukos stock target to $180, keeps overweight By Investing.com - Investing.com Australia
Piper Sandler raises Glaukos stock target to $180, keeps overweight - MSN
Glaukos (NYSE:GKOS) Given Overweight Rating at Piper Sandler - MarketBeat
2,602 Shares in Glaukos Co. (NYSE:GKOS) Purchased by Avior Wealth Management LLC - MarketBeat
(GKOS) Trading Report - Stock Traders Daily
Glaukos (GKOS) Stock Forecast and Price Target 2025 - MarketBeat
Zweig DiMenna Associates LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today - Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 - BioSpace
Riverbridge Partners LLC Sells 163,751 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos (NYSE:GKOS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Glaukos stock soars to all-time high, reaches $161.17 - MSN
Glaukos stock soars to all-time high, reaches $161.17 By Investing.com - Investing.com Canada
Glaukos Co. (NYSE:GKOS) Short Interest Update - MarketBeat
Glaukos Co. (NYSE:GKOS) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Position in Glaukos Co. (NYSE:GKOS) - Defense World
Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Personal Finance - Business Wire
Glaukos Shares Rise Amid Promising Trial Results - TipRanks
GKOS Stock Gains Following Positive Study Data on iDose Platform - MSN
(GKOS) Trading Signals - Stock Traders Daily
Glaukos reports sustained efficacy in iDose TR trials By Investing.com - Investing.com South Africa
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform - BioSpace
Glaukos reports sustained efficacy in iDose TR trials - Investing.com
Glaukos Highlights Advances in Glaucoma Treatments - TipRanks
Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3 - TipRanks
Thomas Burns: The 2-Decade Bet That’s Paying Off - Orange County Business Journal
Here's Why You Should Add Glaukos Stock to Your Portfolio Now - MSN
Harbor Capital Advisors Inc. Makes New Investment in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally? - MSN
Glaukos stock soars to all-time high of $153.72 By Investing.com - Investing.com Nigeria
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):